电影票房

您好,歡迎訪問中山大學腫瘤防治中心官方網站!
職工郵箱 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 元云飛

    職務:肝膽科副主任
    職稱:教授、主任醫師、博士生導師
    專長:肝膽胰腫瘤的外科治療和肝癌的介入治療
    一、基本情況
    職務:肝膽科副主任
    職稱:教授、主任醫師、博士生導師
    專家門診時間: 周一上午;周四上午
    專業特長:主要從事肝移植、肝膽胰腫瘤的外科治療和肝癌的介入治療。在中國率先應用ICGR15評估肝儲備功能,熟練掌握各種復雜的肝切除術(如巨大肝癌切除術、肝尾狀葉切除術、擴大半肝切除術,中肝葉切除術)、高位膽管癌根治術和胰十二指腸切除術等,對各種高難度肝膽外科手術及高危患者的圍手術期處理積累了豐富的經驗。

    二、學習及工作經歷: 
      1978年—1983年:中山醫學院醫學系,獲學士學位
      1983年—1986年:中國醫學科學院血液學研究所工作
      1986年—1989年:中山醫科大學外科學碩士研究生,獲醫學碩士學位
      1989年—1998年:中山大學附屬腫瘤醫院工作
      1998年—2000年:Baylor醫學院進修學習
      2000年—2001年:美國MD Anderson癌癥中心進修學習
      2001年至今:中山大學附屬腫瘤醫院肝膽科工作

      華南腫瘤學國家重點實驗室PI,
      《Chinese Journal of Cancer》雜志(原癌癥雜志)編委(2003.01-至今),
      《嶺南現代臨床外科》雜志編委(2007.03-至今),
      《中華普通外科學文獻(電子版)》雜志編委(2007.08-至今),
      《中華肝臟外科手術學電子雜志》編委(2012.12-至今)
      中國醫師協會外科醫師分會肝臟外科醫師委員會委員(2015.05-至今)
      中華醫學會腫瘤學分會第九屆委員會肝癌學組委員(2013.06-至今)
      中國抗癌協會大腸癌專業委員會肝轉移學組委員(2008.12-至今)
      廣東省抗癌協會肝癌專業委員會委員/常委 ( 2006-至今)
      廣東省醫學會外科學分會委員會委員/常委 (2013.02-至今)
      廣東省抗癌協會大腸癌專業委員會常委 (2012.11-至今)

    E-mail:yuanyf@sysucc.org.cn
            yuanyf@mail.sysu.edu.cn
    Tel & Fax:(+86 20)8734 3118

       1962年10月出生。1983年畢業于中山醫學院,獲學士學位。1983年9月至1986年8月在天津市中國醫學科學院血液學研究所工作。1986年9月回母校讀研究生,師從著名外科學家王吉甫教授。1989年8月畢業,獲醫學碩士學位。1989年9月起在中山 醫科大學腫瘤醫院腹科工作,1998年6月肝膽科成立后一直在肝膽科工作,其中1998.8-2001.8在美國進修學習。1991年晉升為主治醫師,1997年晉升為副教授,2004年破格晉升為臨床研究員,隨后轉聘為腫瘤外科教授、主任醫師。

       主要從事肝膽胰腫瘤的外科治療和肝癌的介入治療。2003年9月開展肝移植治療肝癌。肝移植的開展大大提高了肝外科的手術水平,肝切除術已無手術禁區。熟練掌握各種復雜的肝切除術(如巨大肝癌切除術、肝尾狀葉切除術、擴大半肝切除術,中肝葉切除術等)、高位膽管癌根治術和胰十二指腸切除術等。臨床工作認真負責,外科技術嫻熟,手術精細。

       在國內較早開展肝儲備功能的研究,1992年開始應用吲哚靛青綠15分鐘儲留率(ICGR15)單一指標術前評估肝癌病人肝儲備功能,明顯降低了肝癌切除術后肝功能衰竭發生率[中華腫瘤雜志1995,17:377]。1997年首次提出對于不能切除的肝癌行肝動脈化療栓塞,若肝儲備功能良好,應使用較大劑量lipiodol栓塞,讓lipiodol盡量填滿腫瘤,達到腫瘤最大限度壞死,而不出現肝功能衰竭[癌癥16:358和癌癥16(增刊):39]。在國內較早提出ICGR15評估肝癌病人肝儲備功能具有簡便、實用、較準確等特點。

      近年來,積極開展結直腸癌肝轉移的外科治療和臨床研究,本醫療組每周參加結直腸癌的多學科會診(Multi-Disciplinary Team, MDT)。本院結直腸癌肝轉移的綜合治療在全國具有較好的聲譽,本院大部分結直腸癌肝轉移的外科治療由本醫療組完成。積極參與國際交流,2012年7月在法國巴黎Paul Brousse醫院學習結直腸癌肝轉移的多學科治療。近6年來(2010-2015)本醫療組完成的原發性肝癌和結直腸癌肝轉移外科治療的病例數一直在肝膽科排名第一,并取得了較理想的療效。

      受國家衛生部推薦,于1998年獲得世界衛生組織獎學金。作為訪問學者,1998.9-2000.7在美國Baylor醫學院進修,2000.8-2001.8在美國M.D. Anderson癌癥中心進修。學習腫瘤分子生物學、腫瘤基因治療與肝膽腫瘤的外科治療等。國際上首次發現SYK基因的不表達是由其啟動子過甲基化引起(Cancer Research 2001, 61:5558)。2001年8月回國后,繼續開展腫瘤分子生物學的研究,醫院給本課題組配備了獨立的肝癌分子生物學實驗室和研究助手,獲得多項國家自然科學基金。作為(共同)第一或(共同)通訊作者,論文發表在The Journal of Clinical Investigation, Gastroenterology, Hepatology, Gut, Cancer Research, Clinical Cancer Research, Oncogene等國際知名雜志。同時還致力于肝癌的臨床研究和轉化研究,獲得“中山大學(985工程)轉化醫學研究示范性項目”,“中山大學臨床醫學研究5010計劃項目”和“廣東省高等學校科技創新重點項目”等。

      精心培養研究生,已畢業的研究生留在本院工作,或錄取到中山大學附屬第三醫院和附屬第六醫院,或在廣東、北京、湖南、江西等地三甲醫院工作。其中洪健博士研究生獲得2013年廣東省優秀博士學位論文。

    科研基金:
       (1) 國家自然科學基金面上項目,Rfx6在肝癌干細胞干性特征維持中的作用及機制研究,項目負責人:元云飛,項目編號:81372571,經費:90萬人民幣,2014.01~2017.12。
      (2) 國家自然科學基金面上項目,肝癌Chk1/SYK(L)通路與靶向治療,項目負責人:元云飛,項目編號:81172344,經費:69萬人民幣,2012.01~2015.12。
      (3) 國家自然科學基金面上項目,Chk1 參與肝癌Syk(L)和Syk(S)的表達調控及機制研究,項目負責人:元云飛,項目編號:30972916,經費:32萬人民幣,2010.01~2012.12。
      (4) 國家自然科學基金面上項目,SYK 作為肝癌復發轉移標志物的研究,項目負責人:元云飛,項目編號:30872489,經費:30萬人民幣,2009.01~2011.12。
      (5) 國家自然科學基金專項基金項目(科學部主任基金),SYK 基因與肝細胞癌侵襲性的研究,項目負責人:元云飛,項目編號:30540047,經費:8萬人民幣,2006.01~2006.12。
      (6) 國家重點基礎研究發展計劃(973計劃),腫瘤異質性演化機制與個體治療策略的生物學研究,項目首席科學家:吳仲義,分題骨干,經費:62.5萬,2014.01~2018.12
      (7) 中山大學臨床醫學研究5010計劃項目,精準肝切除與綜合介入治療方案治療肝細胞肝癌合并肝硬化門靜脈高壓癥的臨床隨機對照研究,項目負責人:元云飛,經費:200 萬人民幣,2012 .07~2022.7
      (8) 中山大學(985工程)轉化醫學研究示范性項目,早期肝癌復發轉移相關DNA甲基化表型的篩選和預測體系的建立,項目負責人:元云飛,經費:100萬人民幣,2011~2013。
      (9) 廣東省高等學校科技創新重點項目(廣東省教育廳),肝細胞肝癌合并肝硬化門靜脈高壓癥的治療策略,項目負責人:元云飛,項目編號:CXZD1133,經費:25萬人民幣,2012.1~2014.12。
      (10) 華南腫瘤學國家重點實驗室自主課題,項目負責人:元云飛。
         a) SYK(S)的表達與肝細胞癌預后關系的研究。經費:8萬人民幣,2008。
         b) 不同生物學特征肝細胞癌的異常DNA甲基化模式及其在分子分型中應用的研究,經費:30萬人民幣,2009。
         c) MicroRNA作為診斷標志物用于鑒別肝局灶性結節增生與肝細胞癌的研究,經費:15萬人民幣,2010。
         d) Rfx6與肝癌的發生發展,經費:16.8 萬人民幣,2011。
         e) miR-130b在肝癌發病中的作用及其機制研究,經費:16.8 萬人民幣,2012。
         f) 缺氧微環境下miR-130b-3p 調控肝癌細胞EMT 和轉移的分子機制,經費:25 萬人民幣,2013
         g) Rfx6 在肝癌干細胞干性特征維持中的作用及機制研究, 經費:24.5萬元,2014.
         h) SCAND3在肝癌發病中的作用及其機制研究, 經費:14萬元,2015.
      (11) 985-II 工程項目課題,肝細胞癌腫瘤相關基因甲基化的研究,項目負責人:元云飛,經費:30萬人民幣,2006.1-2007.12
      (12) 美國中華醫學基金會(China Medical Board of New York, Inc.),“SYK gene methylation, SYK protein expression, and Hepatocellular carcinoma invasion.” 課題負責人(PI):元云飛, No: 98-677, US$ 70 000,2003.1~2004.12.  
      (13) 廣東省科技廳科技計劃項目,腫瘤侵襲性相關基因的過甲基化作為肝癌復發轉移標志物的研究,項目負責人:元云飛,項目編號:2002B30107,經費:15萬民幣,2003.1~2005.12。
      (14) 廣東省醫學科學技術研究基金,肝癌SYK基因的過甲基化的研究,項目負責人:元云飛,項目編號:A2002230 ,經費:1萬人民幣. 2002~2004。
      (15) 廣東省教育廳“千百十工程”優秀人才培養基金項目,肝細胞癌SYK、E-cadherin和TIMP-3 基因過甲基化的研究, 項目負責人:元云飛,項目編號:Q校02009,經費:2萬人民幣,2002.9~2005.8.
      (16) 中山大學國家重點學科(腫瘤學)建設基金,肝癌SYK、E-cadherin和TIMP-3 基因過甲基化的研究,課題負責人,經費:10萬人民幣,2003.1~2004.12。
      (17) 中山大學腫瘤中心回國人員啟動基金,肝癌hMLH1基因的過甲基化的研究,項目負責人:元云飛,經費:2萬人民幣, 2003.6~2005.5
      (18) 廣東省科委立項課題,預測肝細胞癌術后轉移與復發的研究,項目負責人:元云飛,經費:2萬人民幣,1996~1999。
      (19) 中山醫科大學腫瘤中心課題,肝儲備功能評估在栓塞化療治療肝癌中的應用研究,項目負責人:元云飛,經費:0.3萬人民幣,1996~1998。
      (20) 中山醫科大學腫瘤中心課題,肝臟儲備功能的綜合評估, 課題負責人:元云飛,經費:0.2萬人民幣,1993~1995年。
      (21) 中山醫科大學腫瘤中心課題,原發性肝癌術前肝儲備功能評估的初步研究,課題負責人:元云飛, 經費:0.35萬人民幣,1991~1993。

    部分論文:
      
    Peer-Reviewed Original Research Articles (* as correspondence author):

    2001-2007:
      (1) Yunfei Yuan, Richard Mendez, Aysegul Sahin, and Jia Le Dai*. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Research 2001, 61(14):5558-5561. (2001 IF=8.302)
      (2) Yunfei Yuan, Hongji Liu, Aysegul Sahin and Jia Le Dai*. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. International Journal of Cancer 2005, 113(4):654–659. (2005 IF=4.7)
      (3) Yunfei Yuan*, Jianping Wang, Jinqing Li, Li Wang, Meixiang Li, Zuli Yang, Changqing Zhang, and Jia Le Dai.  Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma. Clinical Cancer Research 2006, 12(22):6687-6695. (2006 IF=6.177)
      (4) Christina Pramudji, Satoru Shimura, Shin Ebara, Guang Yang, Jianxiang Wang, Chengzhen Ren, Yunfei Yuan, Salahaldin A. Tahir, Terry L. Timme, and Timothy C. Thompson*. In Situ Prostate Cancer Gene Therapy Using a Novel Adenoviral Vector Regulated by the Caveolin-1 Promoter. Clinical Cancer Research, 2001, 7(12):4272-4279.2008:
      (5) Li Xu, Liang Huang, Bin-kui Li, Ya-qi Zhang, Jin-qing Li, Yun-fei Yuan*. Clinicopathologic Features and Long-Term Outcomes of Chinese Patients with Hepatocellular Carcinoma in Non-Cirrhotic Liver. Digestive Surgery 2008, 25(5):376. (2008 IF=1.257)
      (6) Hang Su, Jing Zhao, Yujuan Xiong, Teng Xu, Fan Zhou, Yunfei Yuan, Ying Zhang, Shi-Mei Zhuang*. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutation Research 2008, 641:27-35.
      (7) Xing-Dong Xiong, Jian-Hong Fang, Fu-En Qiu, Jing Zhao, Jiasen Cheng, Yunfei Yuan, Sheng-Ping Li, Shi-Mei Zhuang*. A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma. Mutation Research, 2008, 643:70-74.
      (8) Teng Xu, Ying Zhu, Qing-Kun Wei, Yunfei Yuan, Fan Zhou, Yi-Yuan Ge,JR Yang, H Su, Shi-Mei Zhuang*. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008, 29(11):2126-2131.

    2009:
      (9) Hang Su, Jian-Rong Yang, Teng Xu, Jun Huang, Li Xu, Yunfei Yuan*, Shi-Mei Zhuang*. MicroRNA-101, Downregulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity. Cancer Research 2009, 69(3):1135-42. (2009 IF=7.543)
      (10) Jun Huang, Bin-Kui Li, Gui-Hua Chen, Jin-Qing Li, Ya-Qi Zhang, Guo-Hui Li, Yun-fei Yuan*. Long-Term Outcomes and Prognostic Factors of Elderly Patients with Hepatocellular Carcinoma Undergoing Hepatectomy. Journal of Gastrointestinal Surgery 2009, 13(9):1627-1635. (2009 IF=2.402)

    2010:
      (11) Binkui Li, Wenji Liu, Li Wang, Meixiang Li, Jianping Wang, Liang Huang, Pinzhu Huang, and Yunfei Yuan*. CpG Island Methylator Phenotype Associated with Tumor Recurrence in Tumor-Node-Metastasis Stage I Hepatocellular Carcinoma. Annals of Surgical Oncology, 2010, 17(7):1917-1926. (2010 IF=4.182)
      (12) Binkui Li, Yunfei Yuan*, Guihua Chen, Liru He, Yaqi Zhang, Jinqing Li, Guohui Li, and Wan Yee Lau. Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome? BMC Cancer. 2010, 10:535-43. (2010 IF=3.153)
      (13) Yu-Xiong Feng, Jiang-Sha Zhao, Jing-Jing Li, Tao Wang, Shu-Qun Cheng, Yunfei Yuan, Fudi Wang, Xiao-Fan Wang, Dong Xie*. Liver Cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF- B signaling pathway. Hepatology, 2010, 51(2):535-544.
      (14) Chunxian Zeng, Ruizhi Wang, Daochuan Li, Xue-Jia Lin, Qing-Kun Wei, Yunfei Yuan, Qing Wang, Wen Chen, and Shi-Mei Zhuang*. A Novel GSK-3 beta–C/EBP alpha–miR-122–Insulin-Like Growth Factor 1 Receptor Regulatory Circuitry in Human Hepatocellular Carcinoma. Hepatology 2010, 52:1702-1712.
      (15) Leilei Chen, Tim Hon Man Chan, Yun-Fei Yuan, Liang Hu, Jun Huang, Stephanie Ma, Jian Wang, Sui-Sui Dong, Kwan Ho Tang, Dan Xie, Yan Li, and Xin-Yuan Guan*. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. The Journal of Clinical Investigation. 2010, 120(4):1178-91.
      (16) Hongxing Zhang, Yun Zhai, Zhibin Hu, Chen Wu, Ji Qian, Weihua Jia, Fuchao Ma, Wenfeng Huang, Lixia Yu, Wei Yue, Zhifu Wang, Peiyao Li, Yang Zhang, Renxiang Liang, Zhongliang Wei, Ying Cui, Weimin Xie, Mi Cai, Xinsen Yu, Yunfei Yuan, Xia Xia, Xiumei Zhang, Hao Yang, Wei Qiu, Jingmin Yang, Feng Gong, Minshan Chen, Hongbing Shen, Dongxin Lin, Yi-Xin Zeng, Fuchu He* & Gangqiao Zhou*. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nature Genetics. 2010, 42(9):755-8.
      (17) Ming Shi, Ji-An Chen, Xiao-Jun Lin, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Ya-Qi Zhang, Jin-Qing Li*. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World Journal of Gastroenterology 2010, 16(2): 264-269.
      (18) Guo-Liang Huang, Bin-Kui Li, Mei-Yin Zhang, Hui-Zhong Zhang, Rong-Rong Wei, Yun-Fei Yuan, Ming Shi, Xiao-Qian Chen, Long Huang, An-Hua Li, Bi-Jun Huang, Hong-Hua Li, Hui-Yun Wang*. LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma. World Journal of Gastroenterology 2010, 16(16): 2046-2054.

    2011:
      (19) Liang Huang, Mei-Xiang Li, Li Wang, Bin-Kui Li, Gui-Hua Chen, Li-Ru He, Li Xu, Yun-Fei Yuan*. Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation. Tumor Biology 2011, 32:233-240. (2011 IF=2.143)
      (20) Leilei Chen, Yun-Fei Yuan(co-first), Yan Li, Tim Hon Man Chan, Bo-Jian Zheng, Jun Huang, Xin-Yuan Guan*. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. Gut 2011, 60(4):534-43. (2011 IF=10.111)
      (21) Pinzhu Huang, Jiliang Qiu, Binkui Li, Jian Hong, Canliang Lu, Li Wang, Jianping Wang, Yezhu Hu, Weihua Jia, Yunfei Yuan*. Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clinical Biochemistry 2011, 44:582-589. (2011 IF=2.076)
      (22) Jiliang Qiu, Pinzhu Huang, Qian Liu, Jian Hong, Binkui Li, Canliang Lu, Li Wang, Jianping Wang and Yunfei Yuan*. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. Journal of Translational Medicine 2011, 9:166. (2011 IF=3.474)
      (23) Can-Liang Lu, Ji-Liang Qiu, Pin-Zhu Huang, Ru-Hai Zou, Jian Hong, Bin-Kui Li, Gui-Hua Chen, Yunfei Yuan*. NADPH Oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumor Biology 2011, 32(6):1173-1182. (2011 IF=2.143)
      (24) Jian Li, George Ka-Kit Lau, Leilei Chen, Sui-sui Dong, Hui-Yao Lan, Xiao-Ru Huang, Yan Li, John M. Luk, Yun-Fei Yuan, Xin-yuan Guan*. Interleukin 17A Promotes Hepatocellular Carcinoma Metastasis via NF-kB Induced Matrix Metalloproteinases 2 and 9 Expression. PLoS ONE 2011, 6(7): e21816.
      (25) Xiang-Ming Lao, Dian Wang, Ming Shi, Guipeng Liu, Shengping Li, Rongping Guo, Yunfei Yuan, Minshan Chen, Jinqing Li, Yaqi Zhang* and Xiaojun Lin*. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatology Research 2011, 41(6): 553-563.
      (26) Qian Zhou, Arthur K.-K. Ching, Wilson K.-C. Leung, Carol Y.-Y. Szeto, Shuk-Mei Ho, Paul K.-S. Chan, Yun-Fei Yuan, Paul B.-S. Lai, Winnie Yeo, Nathalie Wong*. Novel therapeutic potential in targeting   microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. International Journal of Oncology 2011, 38(3):721-731.

    2012:
      (27) Jian Hong, Kaishun Hu, Yunfei Yuan*, Yi Sang, Qiangui Bu, Guihua Chen, Longjun Yang, Binkui Li, Pinzhu Huang, Dongtai Chen, Yi Liang, Ruhua Zhang, Jingxuan Pan, Yi-Xin Zeng, and Tiebang Kang*. CHK1 targets spleen tyrosine kinase(L) for proteolysis in hepatocellular carcinoma. The Journal of Clinical Investigation 2012, 122(6):2165-2175. (2012 IF=12.812)
      (28) Qing-an Zeng, Jiliang Qiu, Jian Hong, Yi Li, Shengping Li, Ruhai Zou, Pinzhu Huang, Binkui Li, Yun Zheng, Xiangming Lao and Yunfei Yuan*. Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis. European Journal of Gastroenterology & Hepatology. 2012, 24(5):575-82. (2012 IF=1.915)
      (29) Qing-An Zeng, Jiliang Qiu, Ruhai Zou, Yijie Li, Shengping Li, Binkui Li, Pinzhu Huang, Jian Hong, Yun Zheng, Xiangming Lao, Yunfei Yuan*. Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study. BMC Cancer 2012, 12(1):148. (2012 IF=3.333)
      (30) Ru-hai Zou, An-hua Li, Feng Han, Jiang Hong, Bin-kui Li, Wei Huang, Liang Huang, Yun-fei Yuan*. Liver hypertrophy and accelerated growth of implanted tumors in nonembolized liver of rabbit after left portal vein embolization. Journal of Surgical Research 2012, 178:256-263 (online Apr 2, 2012) (2012 IF=2.018)
      (31) Ji-Liang Qiu, Pin-Zhu Huang, Jing-Hong You, Ru-Hai Zou, Li Wang, Jian Hong, Bin-Kui Li, Kai Zhou, and Yun-fei Yuan*. LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy. Chinese Journal of Cancer 2012, 31(5):223-232. (2014, IF=2.155)
      (32) Dongtai Chen, Wei Xing, Jian Hong, Meibing Wang, Yang Huang, Cuizhen Zhu, Yunfei Yuan, and Weian Zeng*. The Beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Annals of Surgical Oncology 2012, 19:3556–3565
      (33) Pengyuan Yang, Qi-Jing Li, Yuxiong Feng, Yun Zhang, Geoffrey J. Markowitz,  Shanglei Ning, Yuezhen Deng, Jiangsha Zhao, Shan Jiang, Yunfei Yuan, Hong-Yang Wang, Shu-Qun Cheng, Dong Xie*, and Xiao-Fan Wang*. TGF-b-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma. Cancer Cell. 2012, 22(3), 291–303,
      (34) Pinzhu Huang, Jiliang Qiu, Jinghong You, Jian Hong, Binkui Li, Kai Zhou, Guihua Chen, Yunfei Yuan, and Ruhai Zou*. Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers. 2012, 17(5):422-9.
      (35) Tim Hon Man Chan, Leilei Chen, Ming Liu, Liang Hu, Bo-jian Zheng, Vincent Kwok-Man Poon, Pinzhu Huang, Yun-Fei Yuan, Jian-dong Huang, Jie Yang, George Sai-wah Tsao, and Xin-Yuan Guan*. Translationally Controlled Tumor Protein Induces Mitotic Defects and Chromosome Missegregation in Hepatocellular Carcinoma Development. Hepatology 2012, 55:491-505
      (36) Ming Liu, Leilei Chen, Tim Hon Man Chan, Jian Wang, Yan Li, Yan Li, Ting-Ting Zeng, Yun-Fei Yuan, and Xin-Yuan Guan*. Serum and Glucocorticoid Kinase 3 at 8q13.1 Promotes Cell Proliferation and Survival in Hepatocellular Carcinoma. Hepatology 2012, 55:1754-1765
      (37) Guo-Liang Huang, Bin-Kui Li, Mei-Yin Zhang, Rong-Rong Wei, Yun-Fei Yuan, Ming Shi, Xiao-Qian Chen, Long Huang, Hui-Zhong Zhang, Wanqing Liu, Bi-Jun Huang, Honghua Li, Xiao-Feng Zheng, Xian-Rong Luo, Hui-Yun Wang*. Allele Loss and Down-Regulation of Heparanase Gene Are Associated with the Progression and Poor Prognosis of Hepatocellular Carcinoma. PLoS ONE 2012, 7(8): e44061.
      (38) Chan Xie, Li-bing Song, Jue-heng Wu, Jun Li, Jing-ping Yun, Jia-ming Lai, Dong-ying Xie, Bingliang Lin, Yun-fei Yuan, Mengfeng Li*, Zhi-liang Gao*. Upregulator of Cell Proliferation Predicts Poor Prognosis in Hepatocellular Carcinoma and Contributes to Hepatocarcinogenesis by Downregulating FOXO3a . PLoS ONE 2012, 7(7): e40607
      (39) Jian Li, George Lau, Leilei Chen, Yun-Fei Yuan, Jun Huang, John M. Luk, Dan Xie, Xin-Yuan Guan*. Interleukin 23 Promotes Hepatocellular Carcinoma Metastasis via NF-Kappa B Induced Matrix Metalloproteinase 9 Expression. PLoS ONE 2012, 7(9): e46264.

    2013:
      (40) Yan Li, Leilei Chen, Tim Hon Man Chan, Ming Liu, Kar–Lok Kong, Ji–Liang Qiu, Yan Li, Yun–Fei Yuan*, and Xin–Yuan Guan*. SPOCK1 Is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice. Gastroenterology 2013, 144:179-191 (Epub 2012 Sep 25) (2013 IF=13.926)
      (41) J.-L. Qiu, M.-G. Deng, W Li, R.-H. Zou, B.-K. Li, Y Zheng, X.-M. Lao, K Zhou, Y.-F. Yuan*. Hepatic Resection for Synchronous Hepatic Metastasis from Gastric Cancer. European Journal of Surgical Oncology 2013, 39:694-700 (2013 IF=2.843)
      (42) Ruizhi Wang, Na Zhao, Siwen Li, Jian-Hong Fang, Mei-Xian Chen, Jine Yang, Wei-Hua Jia, Yunfei Yuan* and Shi-Mei Zhuang*. MicroRNA-195 Suppresses Angiogenesis and Metastasis of Hepatocellular Carcinoma by Inhibiting the Expression of VEGF, VAV2, and CDC42. Hepatology 2013, 58(2):642-53. (2013 IF=11.19)
      (43) J Gong, J-P Zhang, B Li, C Zeng, K You, M-X Chen, Y Yuan* and S-M Zhuang*. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013, 32(25):3071-9. (2013 IF=8.559)
      (44) Rongrong Wei, Guo-Liang Huang, Mei-Yin Zhang, Bin-Kui Li, Hui-Zhong Zhang, Ming Shi, Xiao-Qian, Chen, Long Huang, Qing-Ming Zhou, Wei-Hua Jia, X.F. Steven Zheng, Yun-Fei Yuan*, and Hui-Yun Wang*. Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma. Clinical Cancer Research 2013, 19(17): 1–12. (2013 IF=8.193)
      (45) Chan Xie, Jueheng Wu, Jingping Yun, Jiaming Lai, Yunfei Yuan, Zhiliang Gao, Mengfeng Li, Jun Li, Libing Song*. MACC1 as a Prognostic Biomarker for Early-Stage and AFP-Normal Hepatocellular Carcinoma. PLoS ONE 2013, 8(5): e64235.
      (46) Leilei Chen, Yan Li, Chi Ho Lin, Tim Hon Man Chan1, Raymond Kwok Kei Chow, Yangyang Song, Ming Liu, Yun-Fei Yuan, Li Fu, Kar Lok Kong, Lihua Qi, Yan Li, Na Zhang, Amy Hin Yan Tong, Dora Lai-Wan Kwong, Kwan Man, Chung Mau Lo, Si Lok, Daniel G Tenen* & Xin-Yuan Guan*. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nature Medicine 2013, 19(2):209-16.
      (47) Qiang Gong, Yong Tao, Jian-Rong Yang, Jun Cai, Yunfei Yuan, Jue Ruan, Jin Yang, Hailiang Liu, Wanghua Li, Xuemei Lu, Shi-Mei Zhuang, San Ming Wang and Chung-I Wu. Identification of medium-sized genomic deletions with low coverage, mate-paired restricted tags. BMC Genomics. 2013, 24;14:51.
      (48) Song Ling Poon, See-Tong Pang, John R. McPherson, Willie Yu,  Kie Kyon Huang, Peiyong Guan, Wen-Hui Weng, Ee Yan Siew, Yujing Liu, Hong Lee Heng, Soo Ching Chong, Anna Gan, Su Ting Tay, Weng Khong Lim, Ioana Cutcutache, Dachuan Huang, Lian Dee Ler, Maarja-Liisa Nairismägi, Ming Hui Lee, Ying-Hsu Chang, Kai-Jie Yu, Waraporn Chan-on, Bin-Kui Li, Yun-Fei Yuan, Chao-Nan Qian, Kwai-Fong Ng, Ching-Fang Wu, Cheng-Lung Hsu, Ralph M. Bunte, Michael R. Stratton, P. Andrew Futreal, Wing-Kin Sung, Cheng-Keng Chuang, Choon Kiat Ong, Steven G. Rozen, Patrick Tan, Bin Tean Teh.  Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool.   Science Translational Medicine 2013, 5:197ra101;
      (49) Zuli Yang, Lijun Huo, Hao Chen, Beibei Ni, Jun Xiang, Liang Kang, Lei Wang, Junsheng Peng, Yunfei Yuan, Jianping Wang*. Hypermethylation and prognostic implication of Syk gene in human colorectal cancer. Medical Oncology 2013, 30(2):586.
      (50) Yingjun Liu, Shengping Li, Xiangbin Wan, Yi Li, Binkui Li, Yaqi Zhang, Yunfei Yuan and Yun Zheng*. Efficacy and safety of thermal ablation in patients with liver metastases. European Journal of Gastroenterology & Hepatology. 2013, 25(4):442-6.
      (51) Xiang-Ming Lao, Guangyu Luo, Liang-Tao Ye, Cheng Luo, Ming Shi, Dian Wang, Rongping Guo, Minshan Chen, Shengping Li*, Xiaojun Lin and Yunfei Yuan. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver International. 2013, 33(4):595-604.
      (52) Yongdong Dai, Lulu Liu, Tingting Zeng, Ying-Hui Zhu, Jiangchao Li, Leilei Chen, Yan Li, Yun-Fei Yuan, Stephanie Ma, Xin-Yuan Guan. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 2013, 436(4):711-8.
      (53) Ru-Hai Zou, Qi-Jiong Li, Ji-Liang Qiu, Ya-Di Liao, Yun-Fei Yuan, An-Hua Li. A modified radiofrequency ablation approach for treating distant lymph node metastasis in two patients with late-stage cancer. Chinese journal of cancer. 2013, 32(10):567-70.
      (54) Ruizhi Wang, Na Zhao, Siwen Li, Jian-Hong Fang, Mei-Xian Chen, Jine Yang, Wei-Hua Jia, Yunfei Yuan, Shi-Mei Zhuang. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology. 2013, 58(2):642-53.

    2014:
      (55) Jian Hong, Yunfei Yuan*, Jianping Wang, Yadi Liao, Ruhai Zou, Chuanlong Zhu, Binkui Li, Yi Liang, Pinzhu Huang, Zongwei Wang, Wenyu Lin, Yixin Zeng, Jia Le Dai, and Raymond T. Chung*. Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma. Cancer Research 2014, 74(6):1845-56 (2014 IF=9.329)
      (56) Binkui Li, Pinzhu Huang, Jiliang Qiu, Yadi Liao, Jian Hong, Yunfei Yuan*. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Medical Oncology, 2014, 31(10): 230. (2014 IF=2.634)
      (57) Jun Huang, Qijiong Li, Yun Zheng, Jingxian Shen, Jiliang Qiu, Binkui Li, Ruhai Zou, Jianping Wang and Yunfei Yuan*. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer 2014, 14:818. (2014 IF=3.362)
      (58) Bin-Kui Li, Pin-Zhu Huang, Ji-Liang Qiu, Ya-Di Liao, Jian Hong and Yun-Fei Yuan*. Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagnostic Pathology 2014, 9:226.(2014 IF=2.597)
      (59) Cong Li, Yangkui Gu, Ming Zhao, Yunfei Yuan, Fenghua Wang, Zhiqiang Wang, Wang Li, Huiyan Luo, Cui Chen, Gong Chen, Peirong Ding, Xiaojun Wu, Zhenhai Lu, Zhizhong Pan, Ruihua Xu, Youjian He, Desen Wan, Yuhong Li. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer chemotherapy and pharmacology. 2014, 4(5):1079-87.
      (60) Stella Chai, Man Tong, Kai Yu Ng, Pak Shing Kwan, Yuen Piu Chan, Tsun Ming Fung, Terence K Lee, Nathalie Wong, Dan Xie, Yun-Fei Yuan, Xin-Yuan Guan, Stephanie Ma. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget. 2014, 5(14):5725-35.
      (61) Longhui Cao, Yi Chang, Wenqian Lin, Jianhua Zhou, Hongying Tan, Yunfei Yuan, Weian Zeng. Long-term survival after resection of hepatocelluar carcinoma: a potential risk associated with the choice of postoperative analgesia. Anesthesia & Analgesia. 2014, 118(6):1309-16.
      (62) Yin Xie, Rong-Rong Wei, Guo-Liang Huang, Mei-Yin Zhang, Yun-Fei Yuan, Hui-Yun Wang. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Medical Oncology. 2014, 31(3):844.
      (63) Ming Liu, Yan Li, Leilei Chen, Tim Hon Man Chan, Yangyang Song, Li Fu, Ting-Ting Zeng, Yong-Dong Dai, Ying-Hui Zhu, Juan Chen, Yun-Fei Yuan, Xin-Yuan Guan. Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma. Gastroenterology. 2014, 146(4):1084-96.
      (64) Lulu Liu, Yongdong Dai, Jinna Chen, Tingting Zeng, Yan Li, Leilei Chen, Ying-Hui Zhu, Jiangchao Li, Stephanie Ma, Dan Xie, Yun-Fei Yuan, Xin-Yuan Guan. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology. 2014, 59(2):531-43.
      (65) Tim Hon Man Chan, Chi Ho Lin, Lihua Qi, Jing Fei, Yan Li, Kol Jia Yong, Ming Liu, Yangyang Song, Raymond Kwok Kei Chow, Vanessa Hui En Ng, Yun-Fei Yuan, Daniel G Tenen, Xin-Yuan Guan, Leilei Chen. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014, 63(5):832-43.

    2015:
      (66) Wei He, Qingli Zeng, Yun Zheng, Meixian Chen, Jingxian Shen, Jiliang Qiu, Miao Chen,  Ruhai Zou, Yadi Liao, Qijiong Li, Xianqiu Wu, Binkui Li* and Yun-Fei Yuan*. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer 2015, 15:263. (2014 IF=3.362)
      (67) Xianqiu Wu, Binkui Li, Jiliang Qiu, Jingxian Shen, Yun Zheng, Qijong Li, Yadi Liao, Wei He, Ruhai Zou and Yunfei Yuan*. Hepatectomy versus hepatectomy with lymphadenectomy in hepatocellular carcinoma – A prospective, randomized controlled clinical trial. Journal of Clinical Gastroenterology 2015;49:520-528(2014 IF=3.498)
      (68) Jiliang Qiu, Yun Zheng, Jingxian Shen, Zeng QingAn, Ruhai Zou, Yadi Liao, Wei He, Qijiong Li, Guihua Chen, Binkui Li, Yunfei Yuan*. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 2015, 158(5):1235-1243.(2014 IF=3.38)
      (69) Lingxi Jiang, Dora Lai-Wan Kwong, Yan Li, Ming Liu, Yun-Fei Yuan, Li Fu, Xin-Yuan Guan*. HBP21, a chaperone of heat shock protein 70, functions as a tumor suppressor in hepatocellular carcinoma. Carcinogenesis. 2015, 36(10):1111-20.
      (70) Yangyang Song, Guangjin Pan, Leilei Chen, Stephanie Ma, Tingting Zeng, Tim Hon Man Chan, Lei Li, Qizhou Lian, Raymond Chow, Xiujuan Cai, Yan Li, Ming Liu, Yun Li, Yinghui Zhu, Nathalie Wong, Yun-Fei Yuan, Duanqing Pei, Xin-Yuan Guan*. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Gastroenterology. 2015, 149(4):1068-81.
      (71) Man Tong, Tsun-Ming Fung, Steve T Luk, Kai-Yu Ng, Terence K Lee, Chi-Ho Lin, Judy W Yam, Kwok Wah Chan, Fai Ng, Bo-Jian Zheng, Yun-Fei Yuan, Dan Xie, Chung-Mau Lo, Kwan Man, Xin-Yuan Guan, Stephanie Ma. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma. Stem Cell Reports. 2015, 5(1):45-59.
      (72) Xue-Jia Lin, Yutian Chong, Zhi-Wei Guo, Chen Xie, Xiao-Jing Yang, Qi Zhang, Sheng-Ping Li, Yujuan Xiong, Yunfei Yuan, Jun Min, Wei-Hua Jia, Yusheng Jie, Min-Shan Chen, Mei-Xian Chen, Jian-Hong Fang, Chunxian Zeng, Yaojun Zhang, Rong-Ping Guo, Yuankai Wu, Guoli Lin, Limin Zheng, Shi-Mei Zhuang. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. The Lancet Oncology. 2015, 16(7):804-15.
      (73) Zhong-Guo Zhou, Xing-Rong Zheng, Qian Zhou, Ming Shi, Yao-Jun Zhang, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Xiao-Jun Lin, Xiang-Ming Lao, Sheng-Ping Li. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese Journal of Cancer. 2015, 34(5):205-16.
      (74) Jian-Hong Fang, Hui-Chao Zhou, Chong Zhang, Li-Ru Shang, Lei Zhang, Jing Xu, Limin Zheng, Yunfei Yuan, Rong-Ping Guo, Wei-Hua Jia, Jing-Ping Yun, Min-Shan Chen, Yaojun Zhang, Shi-Mei Zhuang. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology. 2015, 62(2):452-65.
      (75) Fang Zheng, Yi-Ji Liao, Mu-Yan Cai, Tian-Hao Liu, Shu-Peng Chen, Pei-Hong Wu, Long Wu, Xiu-Wu Bian, Xin-Yuan Guan, Yi-Xin Zeng, Yun-Fei Yuan, Hsiang-Fu Kung, Dan Xie. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genetics. 2015, 11(2):e1004873.
      (76) Jian Wang, Ming Liu, Leilei Chen, Tim Hon Man Chan, Lingxi Jiang, Yun-Fei Yuan, Xin-Yuan Guan. Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility. Oncotarget. 2015, 6(3):1618-30.
      (77) Sheng-Long Ye*, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Christina SM YIP, Zhengguang Lu. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget. 2015, 7(6):6639

    2016
      (78) Pinghua Yang, Jiliang Qiu, Jun Li, Dong Wu, Xuying Wan, Wan Yee Lau, Yunfei Yuan*, and Feng Shen*. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Annals of Surgery 2016, 263(4):778–786 (2014 IF=8.327)

    中文論文(第一作者):
      (1) 元云飛,王吉甫,陳少斌. 大鼠胰腺移植術后尿液血栓素B2排泄量的變化. 中華器官移植雜志, 1992,13(1):5-7
      (2) 元云飛,李國輝,李錦清, 等, 術前肝儲備功能評估對原發性肝癌手術的價值.  中華腫瘤雜志, 1995, 17(5):377-379.          
      (3) 元云飛,李國輝,李錦清,等. 吲哚靛青綠潴留率對評估肝癌手術風險的價值.  癌癥,1996,15(4):277-279
      (4) 元云飛,張亞奇,陳敏山,等. 肝癌術中肝硬化分級的臨床意義. 癌癥,1997,16(1):58-59,62.
      (5) 元云飛,李錦清,張亞奇,等. 肝癌栓塞化療前肝儲備功能評估的臨床意義. 癌癥,1997,16(增刊):39-40
      (6) 元云飛,李錦清,張亞奇,等.  原發性肝癌的二步切除(附13例報告).癌癥,1997,16(5):358-360
      (7) 元云飛, 李錦清, 張亞奇, 陳敏山, 郭榮平, 林小軍, 李國輝. 肝切除術中肝儲備功能評估的臨床意義. 中華外科雜志, 1999, 37(6):327 ( In Brief )
      (8) 元云飛,李錦清, 楊祖立,汪建平. 腫瘤相關基因過甲基化的研究進展. 癌癥. 2002, 21(11):1267-1277. (綜述)
      (9) 元云飛,李斌奎,李錦清,張亞奇,郭榮平,林小軍,李國輝. 巨大肝癌手術切除治療的遠期療效. 癌癥. 2004, 23(7):821-824. 
      (10) 元云飛,崔伯康,張亞奇,李升平,陳敏山,郭榮平,林小軍,陳規劃,李錦清. 原位肝臟移植治療局部晚期肝細胞性肝癌的初步研究--附10例報告. 癌癥. 2004, 23(9):981-984
      (11) 元云飛,李錦清,李斌奎,張亞奇,李國輝.影響肝細胞肝癌切除術后長期生存的相關因素. 中國實用外科雜志.2004,24(10):608-611
      (12) 元云飛,汪建平,李錦清, 王莉,劉文姬、崔伯康,楊祖立,張昌卿. DNA甲基化導致肝細胞癌SYK基因失表達. 中國腫瘤臨床. 2006, 33(6):307-309

    中文論文 (*通訊作者):
      (13) 李斌奎,崔伯康,元云飛*,李錦清,張亞奇,石明,李國輝. 新TNM分期系統對評價手術切除肝癌預后的意義. 癌癥,2005,24(7):769-773
      (14) 黃 俊,李斌奎,元云飛*,崔伯康,李錦清,張亞奇,李國輝. 肝臟局灶性結節性增生38例臨床分析并文獻復習. 癌癥,2005,24(10):1241-1245
      (15) 劉文姬,王 莉,汪建平,李錦清,張昌卿,鄭 列,元云飛*. CpG島甲基化表型和OPCML基因表達與肝細胞癌發生的關系. 癌癥 2006, 25(6):696-700
      (16) 黃 俊,鄭 列,王 莉, 汪建平,李錦清,張昌卿,元云飛*.肝細胞癌hMLH1基因甲基化與肝癌切除術后輔助性TACE療效的關系. 中山大學學報(醫學科學版)2006,27(4S):3-5
      (17) 洪 健, 元云飛*, 李斌奎, 黃亮, 李錦清, 張亞奇, 李國輝. 67例肝細胞肝癌合并重度肝硬化的手術療效分析.癌癥.2007,26(6):620-623
      (18) 黃 俊,元云飛*,李斌奎,李錦清,張亞奇,李國輝。肝切除術治療老年原發性肝癌的效果分析。中華普通外科學文獻(電子版) 2007,1(3):159-162
      (19) 黃 亮,劉繼紅,元云飛*,李斌奎. 上皮性卵巢癌肝轉移的治療及預后影響因素。中華普通外科學文獻(電子版)2008,2(6):479-483
      (20) 盧燦亮,徐 立,李斌奎,李錦清,張亞奇,元云飛*. 原發性肝癌胃轉移1例并文獻復習. 嶺南現代臨床外科 2008,8(3):233
      (21) 黃品助,盧燦亮,李斌奎,洪健,黃亮,王莉,張穎, 元云飛*. OCT4在肝細胞癌中的表達及其臨床意義. 癌癥,2010,29(1):111-116
      (22) 盧燦亮,黃品助,李斌奎,洪健,黃亮,王莉,張穎,元云飛*.NADPH氧化酶DUOX1在肝細胞癌中的表達及臨床意義.中華普通外科學文獻(電子版)2010.4(1):10-15
      (23) 邱際亮,元云飛*,李斌奎,盧燦亮,徐瑞華,潘志忠,李錦清,張亞奇,萬德森.手術切除結直腸癌肝多個轉移瘤的效果分析.中華普通外科學文獻(電子版), 2010, 4(3):203-207
      (24) 洪健,鄒如海,楊龍君,李斌奎,黃品助,元云飛* .肝細胞癌中全長型脾酪氨酸激酶的表達及其預后價值. 中山大學學報(醫學科學版)2011, 32(2):216-218.
      (25) 楊龍君,洪 健,廖亞帝,王 莉,李斌奎,元云飛* .全長型脾酪氨酸激酶對肝細胞癌侵襲和轉移的抑制作用. 中山大學學報(醫學科學版)2012, 33(1):23-27.

        Created on September 28, 2002,
        Updated on April 8, 2016.

訪客通道
員工通道
關注腫瘤醫院
留言建議 ×